A macaque model of HIV-1 infection

Théodora Hatziioannou(Aaron Diamond AIDS Research Center), Zandrea Ambrose(University of Pittsburgh), Nancy P. Y. Chung(National Cancer Institute), Michael Piatak(Pancreatic Cancer Action Network), Fang Yuan(Pancreatic Cancer Action Network), Charles M. Trubey(Pancreatic Cancer Action Network), Vicky Coalter(Pancreatic Cancer Action Network), Rebecca Kiser(Pancreatic Cancer Action Network), Doug Schneider(Pancreatic Cancer Action Network), Jeremy Smedley(National Cancer Institute), Rhonda Pung(National Cancer Institute), Mercy Gathuka(National Cancer Institute), Jacob D. Estes(Pancreatic Cancer Action Network), Ronald S. Veazey(Tulane University), Vineet N. KewalRamani(National Cancer Institute), Jeffrey D. Lifson(Pancreatic Cancer Action Network), Paul D. Bieniasz(Howard Hughes Medical Institute)
Proceedings of the National Academy of Sciences
March 2, 2009
Cited by 159Open Access
Full Text

Abstract

The lack of a primate model that utilizes HIV-1 as the challenge virus is an impediment to AIDS research; existing models generally employ simian viruses that are divergent from HIV-1, reducing their usefulness in preclinical investigations. Based on an understanding of species-specific variation in primate TRIM5 and APOBEC3 antiretroviral genes, we constructed simian-tropic (st)HIV-1 strains that differ from HIV-1 only in the vif gene. We demonstrate that such minimally modified stHIV-1 strains are capable of high levels of replication in vitro in pig-tailed macaque (Macaca nemestrina) lymphocytes. Importantly, infection of pig-tailed macaques with stHIV-1 results in acute viremia, approaching the levels observed in HIV-1-infected humans, and an ensuing persistent infection for several months. stHIV-1 replication was controlled thereafter, at least in part, by CD8+ T cells. We demonstrate the potential utility of this HIV-1-based animal model in a chemoprophylaxis experiment, by showing that a commonly used HIV-1 therapeutic regimen can provide apparently sterilizing protection from infection following a rigorous high-dose stHIV-1 challenge.


Related Papers

No related papers found

Powered by citation graph analysis